Brief: Spectrum Pharmaceuticals Announces Unaudited Q4 2022 Financial Results
31/01/2023 14:28
Jan 31 (Reuters) - Spectrum Pharmaceuticals Inc
SPPI.O :
* SPECTRUM PHARMACEUTICALS PROVIDES UPDATE ON ROLVEDON™
(EFLAPEGRASTIM-XNST) INJECTION AND ANNOUNCES UNAUDITED FOURTH
QUARTER 2022 FINANCIAL RESULTS
* SPECTRUM PHARMACEUTICALS INC - PRELIMINARY UNAUDITED Q4
2022 NET
SALES EXPECTED TO BE APPROXIMATELY $10 MILLION
* SPECTRUM PHARMACEUTICALS - CASH, CASH EQUIVALENTS,
MARKETABLE
SECURITIES OF $75 MILLION AT 12/31/2022, EXPECTED TO EXTEND CASH
RUNWAY THROUGH 2024
Source text for Eikon: ID:nBw5d5dPBa
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary